Hinova Pharmaceuticals Inc. (SHA:688302)

Hinova Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	285.05	438.18	633.44	813.23	1,202	901.22
Short-Term Investments	-	109.16	-	-	-	-
Trading Asset Securities	440.82	310.59	210.49	290.62	366.24	-
Cash & Short-Term Investments	725.86	857.93	843.93	1,104	1,568	901.22
Cash Growth	-20.85%	1.66%	-23.55%	-29.59%	73.97%	-20.85%
Accounts Receivable	26.11	0	-	-	-	-
Other Receivables	0.8	0.51	0.84	1.39	1.67	0.54
Receivables	26.91	0.52	0.84	1.39	1.67	0.54
Inventory	11.41	2.85	0	0.01	0.01	0
Prepaid Expenses	-	-	-	-	-	13.09
Other Current Assets	43.79	45.05	40.77	41.99	41.78	40.38
Total Current Assets	807.97	906.34	885.54	1,147	1,611	955.24
Property, Plant & Equipment	371.57	356.03	328.62	187.99	86.61	12.72
Long-Term Investments	17.41	13.8	113.09	109.98	5	-
Other Intangible Assets	30.6	31.08	30.56	31.21	31.86	-
Long-Term Deferred Charges	-	-	-	0.04	0.08	-
Other Long-Term Assets	0.65	2.51	3.77	15.12	0.21	14.39
Total Assets	1,228	1,310	1,362	1,492	1,735	982.35

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	96.5	4.58	40.63	3.14	2.29	1.31
Accrued Expenses	9.26	38.95	31.09	49.17	69.81	90.45
Short-Term Debt	-	-	-	-	30	-
Current Portion of Leases	-	3.3	3.22	3.77	2.45	2.8
Current Income Taxes Payable	1.74	-	-	-	-	-
Current Unearned Revenue	2.71	3.8	-	-	-	-
Other Current Liabilities	25.94	75.29	72.01	50.76	33.73	96.77
Total Current Liabilities	148.95	125.9	146.95	106.84	138.27	191.33
Long-Term Debt	90	100	-	-	-	-
Long-Term Leases	0.99	2.59	5.83	9.08	3.31	1.11
Long-Term Unearned Revenue	24.16	17.49	16.55	8.55	8.1	1.15
Other Long-Term Liabilities	0.86	0.2	-	-	-	-
Total Liabilities	264.96	246.19	169.33	124.47	149.68	193.59

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	99.02	99.02	99.02	99.02	99.02	74.26
Additional Paid-In Capital	2,592	2,592	2,583	2,558	2,482	1,409
Retained Earnings	-1,727	-1,627	-1,490	-1,290	-996.06	-694.54
Comprehensive Income & Other	-0.33	-0.15	-0.03	0.11	0.14	-0.07
Total Common Equity	963.23	1,064	1,192	1,367	1,585	788.76
Shareholders' Equity	963.23	1,064	1,192	1,367	1,585	788.76
Total Liabilities & Equity	1,228	1,310	1,362	1,492	1,735	982.35

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	103.79	105.89	9.05	12.85	35.76	3.91
Net Cash (Debt)	622.07	752.04	834.88	1,091	1,532	897.31
Net Cash Growth	-23.24%	-9.92%	-23.48%	-28.79%	70.74%	-21.16%
Net Cash Per Share	6.33	7.62	8.41	11.02	16.87	12.07
Filing Date Shares Outstanding	98.41	99.02	99.02	99.02	99.02	74.26
Total Common Shares Outstanding	98.41	99.02	99.02	99.02	99.02	74.26
Working Capital	659.03	780.43	738.59	1,040	1,473	763.91
Book Value Per Share	9.79	10.74	12.04	13.81	16.01	10.62
Tangible Book Value	932.63	1,032	1,162	1,336	1,554	788.76
Tangible Book Value Per Share	9.48	10.43	11.73	13.49	15.69	10.62
Buildings	-	76.25	-	-	-	-
Machinery	-	22.02	17.15	15.49	14.85	11.16
Construction In Progress	-	267.36	314.5	169.54	73.76	3

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error